Carl June
MD, Member of the Scientific Advisory Board
Dr. Carl June is a Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania, Philadelphia, USA and board-certified in internal medicine and oncology. He has extensive clinical experience on cancer immunotherapy and is a pioneer in the application of adoptive T-cell therapy to treat cancer patients. Dr. Carl June initially obtained his medical degree from the Naval Academy in Annapolis and Baylor College of Medicine in Houston. He completed his training in immunology, malaria and transplantation biology at the World Health Organization in Geneva, Switzerland and Fred Hutchinson Cancer Research Center in Seattle, USA, respectively.
He currently leads a research lab focusing on studying lymphocyte biology and developing new T-cell engineering approaches for HIV and cancer, and investigating them in the clinic. Dr. Carl June efforts led to the first successful application of adoptive transfer of chimeric-antigen T-cell receptor (CAR)-T cells in cancer patients, enabling 90 % response rate in leukemic patients. These efforts resulted in the first adoptive T-cell therapy product to receive approval by the US Food and Drug Administration for cancer therapy. In addition, he has co-authored hundreds of peer-reviewed publications and was awarded multiple prizes and distinctions, including the Richard V. Smalley Memorial Award from the Society.
